m＋Medelevator.RU
← Поиск публикаций
The Lancet. Infectious diseases · 2026

Effectiveness of respiratory syncytial virus immunisation in practice.

СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Groenendijk Rosalie W, Franck Zazie, Baral Ranju, Basso Leonardo J, Batista Facundo D, Bonten Marc, Caballero Mauricio T, Clark Andrew, Cohen Cheryl, de Cellès Matthieu Domenech, Esteban Ignacio, Falsey Ann R, Fourati Slim, Graham Barney S, Halasa Natasha, Hartert Tina, Kops Aranka L, Kragten-Tabatabaie Leyla, Kriek Lies, Manzoni Paolo, Marchant David J, Martinon-Torres Federico, Mejias Asuncion, Midulla Fabio, Nakimuli Annettee, Nisar M Imran, Nyiro Joyce U, Piedra Pedro A, Richmond Peter C, Shaaban Farina L, Srikantiah Padmini, Stein Renato T, Tahibo Afshan B, Terstappen Jonne, Viegas Mariana, Vizzotti Carla, Watson Conall H, Wee Liang En, Weinberger Daniel M, Bont Louis J, Mazur Natalie I

Аннотация

Respiratory syncytial virus (RSV) affects all ages, with infants and older adults most affected by severe disease. The RSV prevention landscape includes 39 candidates in clinical development, alongside setbacks such as the discontinuation of a promising paediatric live-attenuated vaccine candidate. Several products have been approved, including a maternal vaccine, infant monoclonal antibodies, and vaccines for older adults and adults at high risk. Due to high cost, implementation of these products remains limited to higher-income settings. Real-world evidence confirms high effectiveness, with emerging benefits beyond respiratory disease, including reduced cardiovascular events in older adults. Despite comparable effectiveness of maternal vaccination and monoclonal antibodies, differences in uptake highlight that product availability alone will not ensure population impact. Achieving uptake requires integration into accessible routine care, recommendation by trusted providers, and context-sensitive delivery strategies. This Review summarises RSV preventive products, real-world effectiveness and uptake, and the opportunity of using communication in translating RSV prevention into impact.